Thallion completes enrollment in Phase II renal carcinoma trial

The open label trial was designed to assess the safety and pharmacokinetic profile of Thallion’s new continuous intravenous formulation of CAP-232, as well as provide efficacy data in patients who had failed to benefit from the current standard of care. The trial was designed to administer 0.48 mg/kg/day of CAP-232 through continuous intravenous infusion for three cycles, each cycle consisting of 21 days of treatment followed by seven days of rest.

Lloyd Segal, CEO of Thallion, said: “We believe that completing enrollment in this study enables us to move ahead and initiate our planned confirmatory Phase II trial of CAP-232 in patients with metastatic melanoma during the first half of 2008.”